Jupiter Topco LLC Takes Position in Sarepta Therapeutics, Inc. $SRPT

Jupiter Topco LLC acquired a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 46,265 shares of the biotechnology company’s stock, valued at approximately $831,000.

Several other institutional investors have also modified their holdings of SRPT. iSAM Funds UK Ltd acquired a new stake in Sarepta Therapeutics in the 3rd quarter valued at about $25,000. Kestra Advisory Services LLC acquired a new position in shares of Sarepta Therapeutics in the 4th quarter worth approximately $25,000. Meeder Asset Management Inc. bought a new stake in shares of Sarepta Therapeutics in the 2nd quarter worth approximately $27,000. Ancora Advisors LLC lifted its stake in Sarepta Therapeutics by 200.0% during the third quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 1,000 shares during the last quarter. Finally, Allworth Financial LP boosted its holdings in Sarepta Therapeutics by 2,098.8% during the third quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock worth $35,000 after buying an additional 1,721 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on SRPT. HC Wainwright reiterated a “buy” rating on shares of Sarepta Therapeutics in a research report on Tuesday, July 28th. Wall Street Zen lowered Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Weiss Ratings downgraded Sarepta Therapeutics from a “sell (d)” rating to a “sell (e+)” rating in a report on Wednesday, August 19th. Piper Sandler decreased their price target on Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating for the company in a research report on Thursday, July 9th. Finally, Wolfe Research raised Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 price target on the stock in a research note on Thursday, July 9th. Nine equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and five have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $25.06.

Sarepta Therapeutics Stock Performance

NASDAQ SRPT opened at $22.50 on Monday. The firm’s 50 day moving average price is $18.26 and its two-hundred day moving average price is $18.47. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.62 and a current ratio of 4.42. Sarepta Therapeutics, Inc. has a twelve month low of $14.68 and a twelve month high of $25.32. The stock has a market cap of $2.38 billion, a price-to-earnings ratio of -7.76, a PEG ratio of 0.32 and a beta of 0.27.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.22 by $0.42. Sarepta Therapeutics had a negative return on equity of 1.60% and a negative net margin of 13.48%.The business had revenue of $401.25 million during the quarter, compared to analysts’ expectations of $366.39 million. During the same quarter last year, the firm posted $2.02 earnings per share. Sarepta Therapeutics’s revenue was down 34.3% compared to the same quarter last year. Equities analysts anticipate that Sarepta Therapeutics, Inc. will post 3.52 EPS for the current year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.